phosphotyrosine has been researched along with Atypical Ductal Hyperplasia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Freydin, B; Hooke, JA; Hyslop, T; Klimowicz, AC; Kovatich, AJ; Liu, C; Magliocco, AM; Nevalainen, MT; Peck, AR; Pequignot, E; Rimm, DL; Rosenberg, AL; Rui, H; Sauter, G; Shriver, CD; Stringer, GA; Tran, TH; Witkiewicz, AK; Yang, N | 1 |
1 other study(ies) available for phosphotyrosine and Atypical Ductal Hyperplasia
| Article | Year |
|---|---|
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Cohort Studies; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Nuclear Proteins; Phosphorylation; Phosphotyrosine; Prognosis; Protein Processing, Post-Translational; STAT5 Transcription Factor; Survival Analysis; Treatment Failure; Tumor Suppressor Proteins; Young Adult | 2011 |